Executive summary. A pharmaceutical dosage form converts an active substance or herbal preparation into a product that can be manufactured consistently, tested, stored and administered predictably. Cannabis flower is itself used medicinally in some European systems, but the wider pharmaceutical opportunity lies in controlled formulations and devices.
Dried cannabis flower
Flower is a complex herbal dosage form with variability in particle structure, moisture, microbiology and volatile content. Packaging, vapour-device compatibility and patient instructions influence use. Standardisation should cover more than THC and CBD alone.
Dried flower remains the least pharmaceutically standardised dosage form in the category — batch-to-batch variability in cannabinoid content and moisture is inherent to the format and should be managed through tighter incoming specifications rather than assumed away.
Oral oils and solutions
Oils allow flexible dosing but require control of solubility, oxidation, bulk homogeneity, fill volume and measuring-device accuracy. Formulation should remain uniform across shelf life and use.
Oral oils and solutions require careful attention to cannabinoid solubility and settling behaviour over shelf life; a formulation that passes release testing may still separate or degrade unevenly if the vehicle and packaging are not co-validated.
Capsules and softgels
Capsules offer fixed dosing and convenient handling. Quality attributes may include assay, content uniformity, dissolution or disintegration, leakage, moisture and shell-fill interaction.
Capsules and softgels introduce shell-fill interaction as a stability risk not present in liquid formulations, and dissolution testing should be developed specifically for the cannabinoid payload rather than borrowed from conventional capsule monographs.
Oromucosal sprays
Sprays combine a formulation with a metering system. Delivered-dose uniformity, priming, pump compatibility and in-use stability are central.
Oromucosal sprays depend on delivered-dose uniformity across the device’s full use life, which requires in-use testing that simulates repeated priming and storage orientation, not just single-dose release testing.
Inhalation products
Metered inhalers, vaporisation cartridges and dry-powder systems require aerosol or vapour characterisation, device performance, emissions assessment and dose-delivery studies. Informal consumer vape technology should not be assumed suitable for medicinal use.
Inhalation products carry the most demanding microbiological specification of any cannabis dosage form, reflecting the direct respiratory exposure route, and should not be tested against oral-product microbial limits.
Topical and transdermal systems
Creams, gels and patches need evidence of content uniformity, release, skin compatibility and, for transdermal systems, permeation and adhesion.
Topical and transdermal systems for cannabinoids remain an emerging category with limited standardised guidance; permeation and local tolerability data should be generated specifically for each formulation rather than extrapolated from oral pharmacokinetic data.
Future dosage forms
Nanoemulsions, buccal films, modified-release tablets and other platforms may improve delivery, but novel formulation claims require proportionate development, stability and clinical evidence.
Emerging dosage forms should be evaluated against the same core quality principles as established forms — novelty in delivery mechanism does not reduce the need for validated analytical methods and a defensible stability programme.
Choosing the form
Selection should be driven by clinical target, dose, onset, duration, patient population, manufacturing capability and regulatory pathway. Commercial familiarity should not override pharmaceutical suitability.
Choosing the right dosage form is ultimately a question of matching patient need, target indication and manufacturing capability — the most sophisticated delivery technology is not the right choice if it cannot be reliably manufactured to specification at commercial scale.
Practical reference table
| Dosage form | Dose flexibility | Key performance test | Main stability risk |
|---|---|---|---|
| Flower | Moderate through patient titration | Identity, assay and vapour compatibility | Moisture and volatile loss |
| Oil | High | Assay, uniformity and device accuracy | Oxidation and precipitation |
| Capsule | Low/fixed | Uniformity and dissolution | Shell-fill interaction |
| Spray | Metered | Delivered-dose uniformity | Evaporation and pump performance |
| Inhalation device | Metered or titratable | Emitted dose and aerosol/vapour profile | Device/formulation interaction |
| Patch | Fixed sustained | Release, permeation and adhesion | Adhesive and drug stability |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Is cannabis flower a pharmaceutical dosage form?
It can be supplied as a medicinal herbal product under certain national frameworks.
Why are oils popular?
They offer flexible dosing and relatively straightforward manufacture, though absorption can vary.
What makes a spray more complex than an oil bottle?
The pump becomes part of dose delivery and must be validated.
Can consumer vape cartridges be used medicinally?
Only if the product and device meet appropriate pharmaceutical quality and safety requirements.
Which dosage form is best?
The answer depends on clinical need, patient population and evidence.
Primary references and guidance
- European Pharmacopoeia dosage-form chapters
- European Pharmacopoeia, Cannabis flower
- ICH Q8(R2)
- ICH Q1A(R2)
- ICH Q6A
- EU GMP Part I, Chapters 5 and 6
- EU GMP Annex 15
- EMA pharmaceutical-development guidance
Confirm the current effective version and national applicability before operational, medical or regulatory use.